Efficacy of MEK inhibition in patients with histiocytic neoplasms.

ABSTRACT: Histiocytic neoplasms are a heterogeneous group of clonal haematopoietic disorders that are marked by diverse mutations in the mitogen-activated protein kinase (MAPK) pathway^1,2. For the 50% of patients with histiocytosis who have BRAF^V600 mutations^3-5, RAF inhibition is highly efficacious and has markedly altered the natural history of the disease^6,7. However, no standard therapy exists for the remaining 50% of patients who lack BRAF^V600 mutations. Although ERK dependence has been hypothesized to be a consistent feature across histiocytic neoplasms, this remains clinically unproven and many of the kinase mutations that are found in patients who lack BRAF^V600 mutations have not previously been biologically characterized. Her

SUBMITTER: Diamond EL 

PROVIDER: S-EPMC6438729 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature